Things Can Change Fast

 

Market Talk

Volatile times.

One day it's AI hoopla. The next day Iran and the Middle East remind markets that continued conflict in energy-rich regions can have consequences.

The prevailing narrative remains that some near-term pain may be worth it if it leads to a more stable world. Markets, however, tend to focus on the immediate effects. Higher oil prices can eventually work their way through the economy, and inflation concerns begin to matter again.

Stock Talk

One area getting renewed attention is the PC and server side of the AI story. Both HP Inc. (HPQ) and Dell Technologies (DELL) surprised investors with earnings and continue to benefit from growing demand for AI-capable systems.

Part of the appeal is flexibility. Their hardware can incorporate processors from multiple vendors, including Intel and AMD, and potentially Nvidia's planned CPU offerings down the road. More competition may be coming, but it does not appear to be slowing enthusiasm for the sector at the moment.

Meanwhile, another AI story continues to develop behind the scenes.

As AI infrastructure expands, attention is increasingly turning toward power efficiency, electrical demand and faster computing. This brings several semiconductor manufacturers and designers into focus.

SkyWater Technology (SKYT) is in the process of being acquired. Wolfspeed (WOLF) remains unprofitable but is viewed by some as a leader in silicon carbide technologies. GlobalFoundries (GFS), meanwhile, remains profitable and continues expanding its manufacturing capabilities both in the United States and abroad.

The Jones Report previously discussed the relationship between GFS and Navitas Semiconductor (NVTS). Navitas designs gallium nitride (GaN) and silicon carbide (SiC) power semiconductors intended to improve electrical efficiency. GFS is expected to manufacture these devices at scale, supporting applications that range from AI infrastructure to industrial power systems.

As an aside, recent IPO Cerebras Systems (CBRS) has introduced a different approach to AI processing using a wafer-scale design roughly the size of a dinner plate. The stock initially surged above $300 following the IPO.

At the time, this report suggested letting the excitement settle and, if interested, considering no more than a single tracking share. The stock later faded below $220 and is floating back and forth.

Did CBRS find a bottom? Nobody knows at the moment.

However, one tracking share can remove much of the emotion while serving as a good "what if?" share to get the feel and follow the story. 

Another area we've been watching is the miners. Despite higher gold prices and some encouraging earnings reports, the group still seems challenged. One concern may be the effect higher energy costs could have on sustaining costs.

One other stock we've been watching is V2X (VVX). It does not receive the attention of many of today's popular stories, yet the stock has quietly earned some respect while continuing to climb. Sometimes steady execution matters.

Quantum computing remains worth watching as well. QBTS continues expanding beyond its traditional annealing roots while benefiting from growing government interest and investment in the sector.

The psychedelic biotech story also continues to develop. CMPS has quietly crept higher while ATAI and HELP remain among the companies attempting to address difficult problems such as addiction and depression. The stories remain speculative, but some continue to watch the space.

Looking at the broader picture, GFS appears to be developing into more than just a traditional chip foundry. The company serves the "electronics of everything" while also expanding into areas such as photonics and advanced power semiconductors.

With an additional $375 million in recent U.S. government funding support, GFS remains a stock that appears to be showing some legs.

As always, investors should size positions accordingly and stay aware.

Things change fast.

Stay watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

Sunday Edition: Decisions, Decisions — Why We Say Some

  

 Decisions, Decisions
 — Why We Say Some

Market Talk

The major indices have reached or approached all-time highs.

The Jones Report is not about mutual funds or leaving it to money managers.

We like stock watching here.

What matters is how your stocks are doing.

Watching is one thing.

Decisions are another.

For active investors, decisions are constantly on the table.

Do you take some greens?

Do you hold?

Do you add?

There is no single answer.

Some positions get trimmed because the risk-reward has changed. Others are held because conviction remains strong.

Large holders, fund flows, sector rotation, short activity and changing sentiment can all affect how a stock trades.

The company may not have changed. The stock can still move.

Stock Talk

Last year, when NVTS was trading in the single digits, the Jones Report looked into why Nvidia was interested in Navitas power chips. The power efficiency advantages of GaN and SiC semiconductors for future data centers were highlighted in earlier reports.

Eventually, the market caught on and the share price responded.

After a run, investors start looking harder at the numbers.

What is the earnings outlook?

That does not mean the story is broken.

It does mean expectations have risen.

The market does not always agree that a stock has gone too far.

Palantir is one example.

Many questioned the valuation. The stock continued higher.

Large institutions face the same basic question.

Do they Buy, Sell or Hold?

Or even lend their shares out to short sellers?

Some maintain conviction and stay on the buy side.

Others decide to take gains and wait.

Nobody knows the future.

That is why we say some.

Protecting your own interests and taking a gain in some is often the right move

It can also help build dry powder for whatever comes next.

Holding because conviction remains strong is often the right move.

The challenge is knowing the difference.

Conviction can come from performance.

A stock that continues to execute, grow and deliver results can justify continuing to hold some.

Recent performance by VVX is one example. The stock has had a strong run, yet continuing to hold some can still make sense based on execution and results.

Conviction holdings can also be different.

Take spec biotech stock ONCY.

Readers may recall the Jones Report's "Trinity Approach" discussion.

Performance is not always measured by earnings.

In biotech, performance can be measured by clinical results, regulatory progress and the steps being taken toward FDA approval.

After looking into the company's approach to building immunity while combining Pelareorep with existing cancer drugs, the science remains intriguing.

Clinical progress, new data releases, FDA interactions and the path toward potential approval can all be watched along the way.

It's a "some" position based on the possibility that something important develops.

And, if it does in biotech?

For the winner, some can be enough.

And some can't hurt too much.

As always, stay watchful.

Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

Still Watching ONCY - Back Over $1

 

ONCY is back over $1.

Readers may recall our Trinity article. We were watching several pieces of the story to see if they started fitting together.

The CRC combo trial pairing ONCY's Pelareorep with bevacizumab, the active ingredient behind Roche's Avastin, is getting underway. Some interest also appears to be forming around the CEO, known for the Ambrx-Johnson & Johnson deal.

If interested, this report does not make buy/sell recommendations, but we do use the term: just some, NOT too much, especially in spec stocks.

It could be some time before the complete "Trinity" combo is tried. BUT some areas are developing that a larger Pharma could be eyeing in the back rooms of their scientists. No guarantees in spec though.

Afterthought: If the biotech success scenario plays out, just some may be enough as a back burner stock to watch.

Reference:

https://stockstowatch.blogspot.com/2025/09/the-trinity-missing-puzzle-piece-to.html

Stay Watchful.

Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

The AI Race Is Heating Up — So Is the Volatility… And Other Stock Talk

 

Stock Talk

We first looked at Cerebras (CBRS) when the stock had already surged over $300 just days after its IPO. At those lofty levels, it felt prudent to wait rather than chase the early hoopla.

Now, after a pullback of roughly 50 points and signs of early investor profit taking, maybe the stock is entering a zone where one or two shares may be enough to get a feel for the trading flow.

One issue now being reported in the AI race is heat. Massive AI centers are drawing growing scrutiny for enormous power demand, cooling requirements and even localized heat impact in urban areas.

Reports are emerging that some locales near massive AI centers are seeing environmental temperatures rise several degrees from the enormous power and cooling demands. Not good.

As AI infrastructure scales, efficiency may eventually matter just as much as raw compute power.

That is one important reason why the CBRS approach — using far more processing on just one large wafer instead of spreading workloads and heat across thousands of separate chips — is capturing investor interest.

At the same time, companies like Navitas Semiconductor (NVTS), focused on advanced power semiconductors built around gallium nitride (GaN) and silicon carbide (SiC) technology, are being set up as part of the AI infrastructure story. More efficient power conversion means less wasted energy and potentially less heat throughout future AI center designs.

None of this changes the fact that NVIDIA still largely controls the current AI landscape. But some investors appear to be watching for alternative approaches as power, heat and scaling issues continue to grow.

Some watch stocks have had powerful runs, only to get hit hard later by insider moves, offerings, profit taking or short theses challenging the stories behind them. That does not mean the stories are broken. It does mean volatility remains part of this AI race.

We already covered the general notion of trimming some gains in previous posts. But if “the suits” believe the story has legs — and now see increasing U.S. government backing behind AI infrastructure and advanced technology — staying the course “in some” while staying aware makes some sense.

Not all stock stories fit the same mold. Some names, like VVX, may appeal more to investors looking for operational growth, earnings and what appear to be solid fundamentals tied to defense infrastructure and technology support. 

Others, like ONCY, remain speculative biotech stories, though recent FDA alignment and treatments aimed at advanced cancers appear to be capturing increasing interest. AVAV at times has behaved almost like a momentum trader stock, where buying weakness and trimming strength may make more sense than chasing spikes.

The common thread may simply be awareness. The stories here do have merit, but volatility, timing and position sizing still matter.

As for CBRS, after the anticipated pullback, the story may now be worth watching more closely.

Stay watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

“Deal” for Now?

 

Memorial Day — a moment to honor those who gave all in defense of freedom.

Reuters says the dollar drifted lower as oil pulled back on talk of a Hormuz “deal.”

That’s the headline. That’s the oil trade. We already decided not to play it.

What about tech, AI and quantum? Some stocks to watch — from last week’s list.
Rotation can last — when the suits believe.

The back-and-forth narrative coming out of Washington and Iran seems inconsistent to those trying to follow it from day to day.

Regarding markets and stocks — pick your narrative.
Whether it matters… that’s the hard part.

Today it’s “deal.”

The tone doesn’t feel so settled.

Markets can be superficial — and may like it that way, for a while.
Until reality has its say.

Maybe just another case of kicking the can down the road.

For how long?

Stay Watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

Watch Stocks Making News — GFS, QBTS and Others

 

Stock Talk

Some tech stocks we watch here are showing up again in current trading and news flow.

GFS moved sharply on reports tied to a U.S. push into quantum technology. We have noted GFS as an understated American foundry. The U.S. government is now involved, and the market is taking notice.

One angle discussed here before ties GFS manufacturing to NVTS power semiconductors aimed at next-generation data center buildouts. That broader infrastructure story is part of the interest.

QBTS also moved with renewed U.S. government attention on quantum computing. These types of stocks can move quickly when themes heat up, as we have seen before.

Elsewhere, some previously noted psychedelic-related stocks such as CMPS, HELP and ATAI remain in the background. CMPS recently noted plans to pursue a New Drug Application (NDA) later this year.

ONCY, discussed here before, had an understated mention of FDA alignment in a Pelareorep combination trial, with two prior complete responses noted. The implications may not yet be fully reflected in the stock.

At times, stocks we watch drift… and then show up again all at once. Something to watch.

If venturing into an interesting, but speculative thesis — some. Size accordingly.

Stay Watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

Cerebras (CBRS) — Worth Watching, Not Chasing

 

Stock Talk

Cerebras (CBRS) — Worth Watching, Not Chasing

This is a story about a recent IPO, Cerebras (CBRS). As a note of caution, do not construe this as a buy suggestion — not yet anyway. In just five days, the stock surged from its $185 IPO price to over $320 before being contested and pulling back toward the $290 area.

All market eyes are watching NVIDIA (NVDA) earnings today — but a new AI contender has stepped onto the field.

Cerebras Systems (CBRS) came public last week, selling 30 million IPO shares and raising about $5.55 billion in the biggest IPO of 2026 so far. Shares priced at $185.

Unlike Nvidia’s approach of linking many GPU chips together, Cerebras built one giant “wafer scale” chip roughly the size of a dinner plate. That chip sits inside a larger rack-mounted system built to run AI workloads.

Not thousands of chips — a handful of very big machines. With Cerebras, scaling comes from adding full systems, each already containing a massive processor.

A good start with inference, where latency matters, with potential training advantages as well by keeping everything on one chip.

CUDA vs Linux — The Software Divide

NVIDIA’s real edge isn’t just the chips. It’s CUDA — the software platform that developers already know and use across the AI world. Cerebras takes a different path, running on a Linux-based system with support for familiar tools like PyTorch, but without CUDA.

The company is not just a lab story. Cerebras systems are in use in a few AI datacenters, but still early in their rollout.

The bulls see a real alternative architecture. The bears see a stock priced for perfection facing NVIDIA’s massive software moat.

The story is drawing buyers, but the price is already being contested at lofty levels.

Early trading has also shown how quickly momentum can shift in a hot IPO, with insider selling and lockup considerations adding to the pressure.

For now, NVIDIA remains the king. But CBRS shows the market is at least willing to explore another path in the AI race — even as early volatility reminds investors that the road may not be smooth.

If and when ready for a new position, even one share may be enough to get a feel for the trading flow, positive or negative. The shares are already pricey, with no earnings likely near term, and getting horse whacked is always a risk.

Maybe let it settle from the early hoopla and investor profit taking, then maybe dabble with a few shares to see.

Stay watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.